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Abstract
Melasma is difficult to treat. Vitamin C, topical and by iontophoresis, has been shown to be useful. When lasers are used,
there is a significant incidence of post-laser hyperpigmentation. There is no single established treatment for the latter. The
case history of a 51-year-old Chinese woman is presented. Intravenous vitamin C appears to be useful in treating this
complication.
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Introduction
Melasma is often difficult to treat. It is more
common in females and is associated with sun
exposure, pregnancy and contraceptive pill use.
When severe, it can be socially embarrassing for
patients. Treatment involves broad-spectrum
(UVA+UVB) sunscreen and topical hydroquinone.
Other lightening agents include retinoic acid (treti-
noin) and azelaic acid. Combination therapies such
as hydroquinone, tretinoin, and corticosteroids are
thought to be superior to monotherapy. Lasers are
used in cases of refractory melasma, but the
incidence of post-inflammatory hyperpigmentation
is high (1), and more so in Asian populations with
higher epidermal melanin content (2). When it
occurs, treatment with hydroquinone cream with
other depigmentating agents speeds its resolution
(3), which can take several months. Intravenous
vitamin use to treat this distressing complication is
described.
Case report
A 51-year-old postmenopausal Chinese woman
presented with significant melasma of many years
duration with no response from sunblock, chemical
peeling and depigmentation cream obtained from
another practitioner (Figure 1). Depigmentation
cream (retinoic acid 0.025%, hydroquinoine 5%
and triaminolone 0.1%) was applied to the affected
area at night. Concurrent vitamin C iontophoresis
was started with some improvement after seven
sessions. However, she developed excessive dryness
from the treatment (Figure 2). A course of monthly
Q-switched 1064 nm Nd:YAG laser treatment with
settings at spot size 7 mm and 2.1 J/cm
2 was added
to the vitamin C iontophoresis regime with some
improvement in the skin condition initially
(Figure 3).
She developed post-laser hyperpigmentation after
11 laser sessions and intravenous vitamin C (7 g)
was added after 18 months of therapy. A total of
three doses of intravenous vitamin C, 7 g each time,
were administered; the first two doses were given a
week apart, 1 month after the laser treatment which
Correspondence: Georgia Siow Kiang Lee, TLC Medical Practice, 27B Lorong Liput, S277738, Singapore. E-mail: tlcfc@singnet.com.sg
(Received 30 March 2008; accepted 7 May 2008)
Figure 1. Before treatment with iontophoresis vitamin C.
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returned for follow-up after a 5-month lapse due to
work commitments with no other treatments pre-
scribed in the interim, when a 12th session of laser
treatment was performed together with a third
concurrent dose of intravenous vitamin C (7g).
She had significant improvement in skin pigmen-
tation after this last session which is lasting without
any post-laser hyperpigmentation noted (Figure 4).
Discussion
Post-laser hyperpigmentation is a significant com-
plication and requires considerable preoperative
counseling and effort in management (4). Patients
with darker skin tones are at a higher inherent risk of
side effects from laser surgery. Although advances in
laser technology and individualized treatment para-
meters have reduced the incidence of undesirable
postoperative sequelae, these risks can never be
completely eliminated. Hence, thorough preopera-
tive preparation and education regarding the risks of
cutaneous laser therapy is essential (5). The Q-
switched (Qs) Nd:YAG laser is specially indicated in
targeting melanin for the treatment of melasma,
although it is associated with a significant incidence
Figure 2. After seven sessions with iontophoresis vitamin C.
Figure 3. After the first (A), second (B), sixth (C), 10th (D) and 11th (E) laser sessions with iontophoresis vitamin C.
Figure 4. After the 12th laser session with three sessions of
intravenous vitamin C.
IV vitamin C to treat post-laser hyperpigmentation 235of post-inflammatory pigmentation. This is espe-
cially distressing to the patient if the indication for
laser therapy is localized hyperpigmentation in the
first place.
There is considerable literature on the topic of
intravenous vitamin C, a strong anti-oxidant, which
plays an important role in maintaining physiological
states. In dermatology, vitamin C is used in the
treatment of various skin problems such as depig-
mentation of hyperpigmented spots (6).
Melanogenesis is caused by enzymatic conversion
of tyrosine to melanin pigments. As ascorbic acid has
the ability to inhibit peroxidase and thus melanin
synthesis, the University of Taiwan has proposed
investigating the use of intravenous vitamin C in
improving skin hyperpigmentation in chronic hemo-
dialysis patients. However, vitamin C has limited
stability and permeability (7). Improving vitamin C
delivery by iontophoresis appears useful (8).
Padayatty et al. studied vitamin C pharmacokinetics,
comparing oral and intravenous routes in 17 healthy
hospitalized volunteers. They concluded that only
intravenous vitamin C produces high plasma con-
centrations (9). Hence, it is logical to postulate that
intravenous vitamin C may be effective in the
treatment of post-laser hyperpigmentation.
The use of high-dose vitamin C in curing a variety
of conditions such as the common cold to cancer is
quite controversial. However, the debate remains
such that the FDA is currently sponsoring a clinical
trial of intravenous vitamin C in cancer. There is
little evidence that ascorbate, as all naturally
occurring substances, has any harmful effects, except
in individuals with a rare genetic predisposition. A
theoretical side effect could be on oxalate metabo-
lism, which predisposes to kidney stones (10).
Animal experiments indicate there is little risk of
overdosage in the regimen used clinically. There is
also a tendency towards hypoglycemia during
intravenous administration.
Conclusion
This case illustrates the typical problems associated
with treating melasma. This includes prolonged
courses of therapy using multiple modalities.
Vitamin C is useful as evidenced by the response
to iontophoresis. But with the added complication of
post-laser hyperpigmentation, it appears that intra-
venous vitamin C in a moderate dose did offer a
significant benefit in this patient. Further experience
is required with vitamin C when administered by the
intravenous route.
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